Calcium is an essential mineral involved in bone metabolism, neuromuscular function, and intracellular signaling. HIV infection and antiretroviral therapy (ART) have been associated with disturbances in mineral metabolism and reduced bone health. This study estimated serum calcium levels in ART naïve and ART treated HIV subjects attending the Rivers State University Teaching Hospital, Port Harcourt, Nigeria, and examined effects of sex, ART duration, regimen and lifestyle factors A cross-sectional study design was employed, involving 180 participants (120 HIV-positive and 60 HIV-negative as controls) within the age range of 18-60 years. Serum calcium was determined by the O-cresolphthalein complexone colorimetric method. Group comparison using one –way ANOVA with Tukey's post hoc test (Graph pad prism version 9.0.0, 121). Results with values of P< 0.05 was considered significant. Results showed a decline in mean serum calcium levels across the three groups (control, ART-naïve and ART treated). Control males had higher calcium than Control females (9.69 ± 0.44 mg/dl: 9.22 ± 0.39 mg/dl; p = 0.0045). ART-naïve patients had reduced calcium (males: 8.47 ± 0.55; females: 8.23 ± 0.43 mg/dl), ART users exhibited the lowest levels (males: 6.34 ± 0.73; females: 6.55 ± 0.67 mg/dl; p<0.0001 across groups), Longer ART duration correlated with progressively lower calcium (approximately 7.16 mg/dl at 3 months to 5.55 mg/dl beyond 6 months; p < 0.05). ART regimen did not affect males but in female’s calcium was higher in subjects on TDF+3TC+DTG versus TDF+3TC+EFV (7.05 ± 0.64 mg/dl vs 6.13 ± 0.49 mg/dl; p = 0.0126). Lifestyle factors showed no significant association. HIV infection and ART especially on longer duration are associated with significant reductions in serum calcium. Routine monitoring and appropriate nutritional supplementation, therapeutic interventions or regimen choice are recommended to mitigate potential bone-related complications.
| Published in | American Journal of Biomedical and Life Sciences (Volume 14, Issue 3) |
| DOI | 10.11648/j.ajbls.20261403.11 |
| Page(s) | 34-40 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2026. Published by Science Publishing Group |
Calcium, Calcium Metabolism, Bone, HIV, ART, Duration of Therapy
Subjects (Number) | Ca2+ (mg/dl) | Age (years) |
|---|---|---|
Control Male (34) | 9.69 ± 0.44 | 29.24 ± 4.47 |
Control Female (26) | 9.22 ± 0.39 | 22.31 ± 2.93 |
t-value | 3.089 | 4.844 |
p-value | 0.0045 | <0.0001 |
Remark | S | S |
Subjects (Number) | Ca2+ (mg/dl) | Age (years) |
|---|---|---|
HIV Naive Male (22) | 8.47 ± 0.55 | 40.18 ± 10.65 |
HIV Naive Female (38) | 8.23 ± 0.43 | 31.37 ± 5.84 |
t-value | 1.386 | 2.944 |
p-value | 0.1766 | 0.0064 |
Remark | NS | S |
Subjects (Number) | Ca2+ (mg/dl) | Age (years) |
|---|---|---|
HIV Male (28) | 6.34 ± 0.73 | 33.00 ± 4.72 |
HIV Female (32) | 6.55 ± 0.67 | 34.62 ± 7.73 |
t-value | 0.7614 | 0.5803 |
p-value | 0.4528 | 0.5663 |
Remark | NS | NS |
Subjects | Ca2+ (Males) | Ca2+ (Females) |
|---|---|---|
Control | 9.69 ± 0.44a (34) | 9.22 ± 0.39a (26) |
ART - Naive | 8.47± 0.55b (22) | 8.23 ± 0.43b (38) |
ART- Treated | 6.34 ± 0.73c (28) | 6.55 ± 0.15c (32) |
F-value | 108.8 | 114.4 |
p-value | <0.0001 | <0.0001 |
Remark | S | S |
Physical Activity | Ca2+ (mg/dl) | Alcohol Consumption | Ca2+ (mg/dl) |
|---|---|---|---|
Yes (24) | 9.68 ± 0.52 | Yes (14) | 9.51 ± 0.31 |
No (10) | 9.69 ± 0.42 | No (20) | 9.71 ± 0.46 |
t-value | 0.0487 | F-value | 0.5202 |
p-value | 0.9618 | p-value | 0.6105 |
Remark | NS | Remark | NS |
Alcohol Consumption | Ca2+ (mg/dl) |
|---|---|
Yes (10) | 8.57 ± 0.47 |
No (12) | 8.30 ± 0.71 |
t-value | 0.7717 |
p-value | 0.4601 |
Remark | NS |
Duration | Ca2+ (Males) | Ca2+ (Females) |
|---|---|---|
3 months | 7.16 ± 0.15a (10) | 7.44 ± 0.29a (11) |
6 months | 6.13± 0.48b (12) | 6.44 ± 0.36b (15) |
> 6 months | 5.55 ± 0.07c (6) | 5.57 ± 0.06c (6) |
F-value | 14.14 | 33.10 |
p-value | 0.005 | <0.0001 |
Remark | S | S |
ART Regimen | Ca2+ (Males) | Ca2+ (Females) |
|---|---|---|
TDF+3TC+EFV | 6.70 ± 0.56 (11) | 6.13 ± 0.49a (9) |
TDF+3TC+DTG | 6.17± 0.78 (17) | 7.05 ± 0.64b (18) |
AZT+TDF+3TC+ATV/r | ------------------- | 6.91 ± 0.61c (5) |
F-value | t value -1.044 | 5.630 |
p-value | 0.3312 | 0.0126 |
Remark | NS | S |
HIV | Human Immunodeficieny Virus |
ART | Antiretroviral Therapy |
ANOVA | Analysis of Variance |
PTH | Parathyroid Hormone |
TDF | Tenofovir Disproxil Fumarate |
TAF | Tenofovir Alafenamide |
INSTIs | Integrase Strand Transfer Inhibitors |
TNF | Tumour Necrosis Factor |
IL-6 | Interleukin -6 |
AIDS | Acquired Immunodeficiency Syndrome |
PLHIV | People Living with Human Immunodeficieny Virus |
RSUTH | Rivers State University Teaching Hospital |
O CPC | O cresolphthalein Complexone |
Ca | Calcium |
3TC | Lamivudine |
EFV | Efavirenz |
DTG | Dolutegravir |
AZT | Zidovudine |
ATV/r | Atazanavir/Ritonavir |
SD | Standard Deviation |
UNAIDS | The Joint United Nations Programme on HIV/AIDS |
| [1] | Fauci, AS Braunwald, E.., Kasper, DL., Hauser, SL., Longo, DL., & Jameson, JL. (Eds.). Harrison's principles of internal medicine (20th ed.). 2018. McGraw-Hill Education. |
| [2] | Bikle, D. & Christakos, S. New aspects of vitamin D metabolism and action – Addressing the skin as source and target. Nature Reviews Endocrinology, 2020, 16, 234–252. |
| [3] | Delpino MV and Quarleri J. Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis. Frontiers in. Endocrinology, 2020, 11, 502. |
| [4] | Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, Mitchell DM, Vokes TJ, Winer KK & Shoback DM. Hypoparathyroidism. Nat Rev Dis Primers. 2017, 17055. |
| [5] | Hanna, RM., Ahdoot, RS., Kalantar-Zadeh, K., Ghobry, L., & Kurtz, I. Calcium transport in the kidney and disease processes. Frontiers in Endocrinology, 2022, 12, 762130. |
| [6] | Ravat Z, Hassan-Smith Z & Gittoes N. Hypocalcaemia, Medicine, 2025, 53(10), 678-682, SSN 1357-3039, |
| [7] |
UNAIDS. Global HIV & AIDS statistics — Factsheet. 2023,
https://www.unaids.org/sites/default/files/media_asset/2023-unaids-factsheet_en.pdf |
| [8] | National Agency for the Control of AIDS (NACA). (2022). Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) 2021 Report. Abuja, Nigeria: NACA. |
| [9] | Gibert CL, Wheeler DA, Collins G, Madans M, Muurahainen N, Raghavan SS, & Bartsch G. Randomized, controlled trial of caloric supplements in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. Journal of Acquired Immune Deficiency Syndrome, 1999, 1, 22(3), 253-259. |
| [10] | Azarboo A, Hemmatabadi M, Fahimfar N, Faghihi Z, SeyedAlinaghi S, Shirzad N & Abbasian L. Evaluation of bone mineral density and its influencing factors in patients infected with HIV under antiretroviral therapy. BMC Infectious Disease. 2025, 25(1), 33. |
| [11] | Wang J, Chung S, Wu P et al. Optimizing bone health in people living with HIV: insights from a network meta-analysis of randomized controlled trials. eClinicalMedicine, 2025; 81: 103103 Published Online 17 February 2025 |
| [12] | Nishijima T, Gatanaga H, Oka S. Tenofovir nephrotoxicity among Asians living with HIV: review of the literature. Global Health & Medicine. 2019, 31, 1(2), 88-94. |
| [13] | Sax, PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Hans-Jürgen S, Andrea A, Kimberly W, Jihad S, Jacques R, Will G, Joseph C, Kirsten W, Devi S, Andrew C, & Erin Q, Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial, The Lancet, 2017, 390, 10107, 2073-2082, SSN 0140-6736, |
| [14] | Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H & Quirk E. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018, 5(7), e347-e356. |
| [15] | Pramukti I, Lindayani L, Chen YC, Yeh CY, Tai TW, Fetzer S & Ko NY. Bone fracture among people living with HIV: A systematic review and meta-regression of prevalence, incidence, and risk factors. PLoS One. 2020, 15(6): e0233501. |
| [16] | Ilha TASH, Comim FV, Copes RM, Compston JE, & Premaor MO. HIV and Vertebral Fractures: a Systematic Review and Metanalysis. Science Report. 2018, 18, 8(1), 7838. |
| [17] | Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Yin MT. Vitamin D and Calcium Attenuate Bone Loss with Antiretroviral Therapy Initiation: A Randomized Trial. Ann Intern Med. 2015, 162(12), 815-824. |
| [18] | Sajeed, S. & Shetkar, NR. Study of Serum Magnesium, Potassium and Calcium in Acute Myocardial Infarction Patients. Biomedical and Pharmacology Journal, 2023, 16(4), 2173-2176. |
| [19] | Brown, TT. Hoy, J. Borderi, M. Guaraldi, G. Renjifo, B. Vescini, F. Yin, MT. & Powderly, WG. Recommendations for evaluation and management of bone disease in HIV. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 2015, 60(8), 1242–1251. |
| [20] | Vlot MC, Grijsen ML, Prins JM, de Jongh RT, de Jonge R, den Heijer M & Heijboer AC. Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection. PLoS One. 2018, 9; 13(3): e0193679. |
| [21] | Dumitrescu F, Dragonu L, Marcu EA, Pădureanu V, Stoian AC, Rădoi-Troacă CL, Pădureanu R, Duduveche A, Georgescu IA & Giubelan L. Bone Mineral Density in HIV-Infected People-the Experience of Craiova Regional Center. Biomedicines, 2025, 20; 13(9): 2305. |
| [22] | Ahmed M, Mital D, Abubaker NE, Panourgia M, Owles H, Papadaki I & Ahmed MH. Bone Health in People Living with HIV/AIDS: An Update of Where We Are and Potential Future Strategies. Microorganisms. 2023, 19; 11(3): 789. |
| [23] | Ugochukwu C., Waribo, HA & Onwuli, DO. Comparative Evaluation of the Levels of CD4+ and CD8+ T-Cells, Viral Load, and Some Immunomodulatory Trace Elements in ART and ART-naive HIV Patients in Port Harcourt, Nigeria. Asian Journal of Medicine and Health. 2021, 19(9): 127-133. Article no AJMAH. 72697. |
| [24] | Lopes, JB., Figueiredo, CP., Caparbo, VF., Takayama, L., Menezes, PR., Scazufca, M., & Pereira, RM. Osteoporotic fractures in the Brazilian community-dwelling elderly: prevalence and risk factors. Journal of Clinical Densitometry: the official Journal of the International Society for Clinical Densitometry, 2011, 14(3), 359–366. |
| [25] | González-Molero, I., Morcillo, S., Valdés, S., Pérez-Valero, V., Botas, P., Delgado, E., Hernández, D., Olveira, G., Rojo, G., Gutierrez-Repiso, C., Rubio-Martín, E., Menéndez, E., & Soriguer, F. Vitamin D deficiency in Spain: a population-based cohort study. European Journal of Clinical Nutrition, 2011, 65(3), 321–328. |
| [26] | Kiran, N., Kanth, M., Satyannarayana, V., & Kumar, P. Serum calcium and phosphorus levels in HIV-positive patients under treatment. International Journal of Clinical Biochemistry and Research, 2020, 7(2), 164–167. |
| [27] | Abdollahi, A., Shoar, S., Jafari, S., & Shoar, N. Impacts of highly active antiretroviral therapy (HAART) on metabolic status of patients with AIDS: What happens from the initiation of AIDS to the initiation of treatment? Journal of Research in Medical Sciences: the official journal of Isfahan University of Medical Sciences, 2014, 19(3), 246–250. |
| [28] | Godos, J., Giampieri, F., Chisari, E., Micek, A., Paladino, N., Forbes-Hernández, TY. & Grosso, G. Alcohol consumption, bone mineral density, and risk of osteoporotic fractures: a dose–response meta-analysis. International Journal of Environmental Research and Public Health, 2022, 19(3), 1515. |
| [29] |
Chongyangyuenvong P & Kiertiburanakul S. Changes in Metabolic Parameters After Switching from Efavirenz to Dolutegravir-Based Regimen: A Cohort Study in Thai People Living With HIV. J Int Assoc Provid AIDS Care, 2026, 25: 23259582261432459.
https://doi.org/10.1177/23259582261432459 Epub 2026 Mar 10. |
| [30] | Venter, WDF., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., Norris, S., Chersich, M., Clayden, P., Abrams, E., Arulappan, N., Vos, A., McCann, K., Simmons, B., & Hill, A. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. The New England Journal of Medicine, 2019, 381(9), 803–815. |
| [31] | Zucker, I., & Prendergast, BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology of Sex Differences, 2020, 11(1), 32-54. |
| [32] | Moges, TA., Akalu, TY. & Sema, FD. Unintended medication discrepancies and associated factors upon patient admission to the internal medicine wards: identified through medication reconciliation. BMC Health Serv Res, 2022, 22, 1251. |
APA Style
Waribo, H. A., Meniel, A. L., Ogu-Nweke, E. (2026). Evaluation of Calcium Levels Among HIV Patients Attending RSUTH: ART- Naïve Versus ART Experienced. American Journal of Biomedical and Life Sciences, 14(3), 34-40. https://doi.org/10.11648/j.ajbls.20261403.11
ACS Style
Waribo, H. A.; Meniel, A. L.; Ogu-Nweke, E. Evaluation of Calcium Levels Among HIV Patients Attending RSUTH: ART- Naïve Versus ART Experienced. Am. J. Biomed. Life Sci. 2026, 14(3), 34-40. doi: 10.11648/j.ajbls.20261403.11
@article{10.11648/j.ajbls.20261403.11,
author = {Helen Anthony Waribo and Adulphus Levi Meniel and Evidence Ogu-Nweke},
title = {Evaluation of Calcium Levels Among HIV Patients Attending RSUTH: ART- Naïve Versus ART Experienced},
journal = {American Journal of Biomedical and Life Sciences},
volume = {14},
number = {3},
pages = {34-40},
doi = {10.11648/j.ajbls.20261403.11},
url = {https://doi.org/10.11648/j.ajbls.20261403.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20261403.11},
abstract = {Calcium is an essential mineral involved in bone metabolism, neuromuscular function, and intracellular signaling. HIV infection and antiretroviral therapy (ART) have been associated with disturbances in mineral metabolism and reduced bone health. This study estimated serum calcium levels in ART naïve and ART treated HIV subjects attending the Rivers State University Teaching Hospital, Port Harcourt, Nigeria, and examined effects of sex, ART duration, regimen and lifestyle factors A cross-sectional study design was employed, involving 180 participants (120 HIV-positive and 60 HIV-negative as controls) within the age range of 18-60 years. Serum calcium was determined by the O-cresolphthalein complexone colorimetric method. Group comparison using one –way ANOVA with Tukey's post hoc test (Graph pad prism version 9.0.0, 121). Results with values of P< 0.05 was considered significant. Results showed a decline in mean serum calcium levels across the three groups (control, ART-naïve and ART treated). Control males had higher calcium than Control females (9.69 ± 0.44 mg/dl: 9.22 ± 0.39 mg/dl; p = 0.0045). ART-naïve patients had reduced calcium (males: 8.47 ± 0.55; females: 8.23 ± 0.43 mg/dl), ART users exhibited the lowest levels (males: 6.34 ± 0.73; females: 6.55 ± 0.67 mg/dl; p<0.0001 across groups), Longer ART duration correlated with progressively lower calcium (approximately 7.16 mg/dl at 3 months to 5.55 mg/dl beyond 6 months; p < 0.05). ART regimen did not affect males but in female’s calcium was higher in subjects on TDF+3TC+DTG versus TDF+3TC+EFV (7.05 ± 0.64 mg/dl vs 6.13 ± 0.49 mg/dl; p = 0.0126). Lifestyle factors showed no significant association. HIV infection and ART especially on longer duration are associated with significant reductions in serum calcium. Routine monitoring and appropriate nutritional supplementation, therapeutic interventions or regimen choice are recommended to mitigate potential bone-related complications.},
year = {2026}
}
TY - JOUR T1 - Evaluation of Calcium Levels Among HIV Patients Attending RSUTH: ART- Naïve Versus ART Experienced AU - Helen Anthony Waribo AU - Adulphus Levi Meniel AU - Evidence Ogu-Nweke Y1 - 2026/05/30 PY - 2026 N1 - https://doi.org/10.11648/j.ajbls.20261403.11 DO - 10.11648/j.ajbls.20261403.11 T2 - American Journal of Biomedical and Life Sciences JF - American Journal of Biomedical and Life Sciences JO - American Journal of Biomedical and Life Sciences SP - 34 EP - 40 PB - Science Publishing Group SN - 2330-880X UR - https://doi.org/10.11648/j.ajbls.20261403.11 AB - Calcium is an essential mineral involved in bone metabolism, neuromuscular function, and intracellular signaling. HIV infection and antiretroviral therapy (ART) have been associated with disturbances in mineral metabolism and reduced bone health. This study estimated serum calcium levels in ART naïve and ART treated HIV subjects attending the Rivers State University Teaching Hospital, Port Harcourt, Nigeria, and examined effects of sex, ART duration, regimen and lifestyle factors A cross-sectional study design was employed, involving 180 participants (120 HIV-positive and 60 HIV-negative as controls) within the age range of 18-60 years. Serum calcium was determined by the O-cresolphthalein complexone colorimetric method. Group comparison using one –way ANOVA with Tukey's post hoc test (Graph pad prism version 9.0.0, 121). Results with values of P< 0.05 was considered significant. Results showed a decline in mean serum calcium levels across the three groups (control, ART-naïve and ART treated). Control males had higher calcium than Control females (9.69 ± 0.44 mg/dl: 9.22 ± 0.39 mg/dl; p = 0.0045). ART-naïve patients had reduced calcium (males: 8.47 ± 0.55; females: 8.23 ± 0.43 mg/dl), ART users exhibited the lowest levels (males: 6.34 ± 0.73; females: 6.55 ± 0.67 mg/dl; p<0.0001 across groups), Longer ART duration correlated with progressively lower calcium (approximately 7.16 mg/dl at 3 months to 5.55 mg/dl beyond 6 months; p < 0.05). ART regimen did not affect males but in female’s calcium was higher in subjects on TDF+3TC+DTG versus TDF+3TC+EFV (7.05 ± 0.64 mg/dl vs 6.13 ± 0.49 mg/dl; p = 0.0126). Lifestyle factors showed no significant association. HIV infection and ART especially on longer duration are associated with significant reductions in serum calcium. Routine monitoring and appropriate nutritional supplementation, therapeutic interventions or regimen choice are recommended to mitigate potential bone-related complications. VL - 14 IS - 3 ER -